Eun C Lee

RE39588, Apr 24, 2007

Oct 31, 1990

07/606462

Eun Soo Lee - Redwood City CA, US
Su Il Yum - Los Altos CA, US

Alza Corporation - Mountain View CA

A61F 3/00

424449, 424448, 424484

A diffusional drug delivery device is described which can provide for stability of the adhesive and system components, elimination of the initial burst of drug and hence irritation, and to provide for delayed onset of therapeutic effect along with delivery of a therapeutic agent at an optimum rate. The therapeutic agent in a first form which is suitable for storage, and the anhydrous activating means are inert when in an anhydrous environment. Moisture activates the system whereby the activating means provides an acidic or basic solution and the first form of the therapeutic agent is converted to a second form which is suitable for absorption through the skin or mucosa.

7244738, Jul 17, 2007

Jul 2, 2004

10/884768

Terrence Joseph Connolly - Redwood City CA, US
Paul Francis Keitz - Redwood City CA, US
Eun Kyung Lee - San Jose CA, US
Jim Li - San Jose CA, US
Francisco Javier Lopez-Tapia - Union City CA, US
Patrick Finbar McGarry - Mountain View CA, US
Chris Richard Melville - Palo Alto CA, US
Dov Nitzan - San Jose CA, US
Counde O'Yang - Sunnyvale CA, US
Fernando Padilla - Fremont CA, US
Klaus Kurt Weinhardt - San Francisco CA, US

Roche Palo Alto LLC - Palo Alto CA

A61K 31/517
A01N 43/54
C07D 239/72
A61K 31/549
C07D 417/02
C07D 285/26

5142663, 5142662, 544287

Compounds represented by Formula I:.

20060171906, Aug 3, 2006

Dec 21, 2005

11/315423

Parminder Singh - Union City CA, US
Eun Lee - Redwood City CA, US
Appala Sagi - Redwood City CA, US
Mikhail Feldstein - Moscow, RU
Danir Bairamov - Sunnyvale CA, US

Corium International, Inc. - Redwood City CA
A.V. Topchiev Institute of Petrochemical Synthesis Russian Academy of Sciences - Moscow

A61K 8/22

424053000

A new tooth whitening composition provides sustained release of high levels of whitening agent and is moisture-activated without significant swelling. A preferred system for applying the composition to the teeth is flexible, self-adhesive, and well-tolerated by users. In certain embodiments the tooth whitening composition comprises a mixture of tooth whitening agents, with a first whitening agent selected so as to release peroxide gradually upon contact with moisture and produce an alkaline pH, and a second whitening agent selected so as to release peroxide rapidly upon contact with moisture.

20060182788, Aug 17, 2006

Jan 27, 2006

11/341085

Parminder Singh - Union City CA, US
Eun Lee - Redwood City CA, US
Appala Sagi - Redwood City CA, US
Mikhail Feldstein - Moscow, RU
Danir Bairamov - Sunnyvale CA, US

A61F 13/02
A61L 15/16

424448000, 442123000

This invention relates to the use of hydrophilic, biocompatible adhesives in drug delivery systems, wound dressings, bioelectrodes, and other systems in which hydrophilic, biocompatible adhesives are desirable. In particular, the invention relates to water-swellable, water-insoluble polymers that in combination render a composition adhesive upon contact with moisture, wherein a first water-swellable, water-insoluble polymer is cationic, a second water-swellable, water-insoluble polymer is anionic, and the polymers are ionically associated with each other to form a polymer matrix.

20070265446, Nov 15, 2007

Jun 22, 2007

11/821493

Terrence Connolly - Redwood City CA, US
Paul Keitz - Redwood City CA, US
Eun Lee - San Jose CA, US
Jim Li - San Jose CA, US
Francisco Lopez-Tapia - Union City CA, US
Patrick McGarry - Mountain View CA, US
Chris Melville - Palo Alto CA, US
Dov Nitzan - San Jose CA, US
Counde O'Yang - Sunnyvale CA, US
Fernando Padilla - Fremont CA, US
Klaus Weinhardt - San Francisco CA, US

C07D 239/88
C07D 401/02

544284000, 544287000

Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R′, Rand Rare as defined herein.

20100291186, Nov 18, 2010

Jan 14, 2010

12/687586

Parminder Singh - Union City CA, US
Eun Soo Lee - Redwood City CA, US
Amit K. Jain - Milpitas CA, US

A61K 9/70
A61K 31/18
A61P 13/08

424449, 514603

In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier.

58434682, Dec 1, 1998

May 13, 1996

8/644922

Terry L. Burkoth - Oxford, GB2
Lina T. Taskovich - Palo Alto CA
Russell D. Beste - Mountain View CA
Robert M. Gale - Los Altos CA
Eun Soo Lee - Redwood City CA
Richard D. Hamlin - Newark CA
Su LL Yum - Los Altos CA

ALZA Corporation - Palo Alto CA

A61F 1302

424448

Compositions, devices, and methods for transdermal administration of an active agent are disclosed using a novel dual permeation enhancer mixture comprising lauryl acetate and a monoglyceride, preferably glycerol monolaurate. The dual permeation enhancer mixture comprising lauryl acetate is a potent permeation enhancer and provides stable systems which are more readily characterized.

52367142, Aug 17, 1993

Nov 1, 1988

7/265738

Eun S. Lee - Redwood City CA
Victor Goetz - Philadelphia PA

Alza Corporation - Palo Alto CA

A61F 1300

424449

Compositions and dosage forms for administering abusable substances are disclosed which have a reduced potential for abuse without diminishing the therapeutic or beneficial effects of the abusable substance. Topical compositions for application to the skin or mucosa contain the abusable substance in a form which is permeable to the skin or mucosa to which it is to be applied and an antagonist for the abusable substance is present in the composition in an abuse negating amount and in a form that is impermeable to the skin or mucosa to which the composition is to be applied. Controlled release dosage forms which release the abusable substance from a drug reservoir composition confined behind a release rate controlling barrier have the abusable substance and its antagonist in the drug reservoir. The abusable substance is present in a form that is releasable from the dosage form and the antagonist is present in an abuse negating amount in a form that is not releasable from the dosage form. Thus the compositions and dosage forms of this invention permit the therapeutic use, at substantially full potency, of an abusable substance when use as prescribed but reduce the abuse potential of the compositions and dosage forms by other routes of administration.